language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
LHLH

$272.2

+1.91
arrow_drop_up0.71%
Market closed·update03 Feb 2026 21:00

$272.19

-0.01
arrow_drop_down0.00%
Post-market·update04 Feb 2026 00:58
Day's Range
269.545-275.49
52-week Range
209.38-293.72

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2026-02-17
Next Earnings TimeBefore Market Open
Volume394.05K
Average Volume 30d793.35K

AI LH Summary

Powered by LiveAI
💰
25.5
Valuation (P/E Ratio)
Reasonable for growth sector
📈
0.152
EPS Growth (YoY)
Strong earnings growth
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
78

Labcorp Holdings Inc. demonstrates strong fundamental performance with consistent earnings growth and a solid balance sheet. While thematic tailwinds in healthcare diagnostics are present, current technical indicators suggest a potential for short-term consolidation. Recommended for investors seeking long-term stability and growth in the healthcare sector.

Moderate

Thematic

70

Labcorp benefits from several positive thematic trends in healthcare, including the increasing demand for diagnostic testing and personalized medicine. However, the competitive landscape and evolving healthcare policies present some challenges.

Strong

Fundamental

85

Labcorp exhibits robust financial health, characterized by improving profitability, consistent revenue generation, and a manageable debt level. Strong free cash flow and effective revenue-to-profit conversion further bolster its fundamental strength.

Neutral

Technical

65

Labcorp's stock exhibits a mixed technical picture. While long-term moving averages suggest an uptrend, short-term indicators like RSI and MACD point towards potential overbought conditions and a possible consolidation phase.

FactorScore
Healthcare Diagnostics Demand85
Personalized Medicine & Genetics75
Healthcare Policy & Reimbursement55
Competition in Lab Services65
FactorScore
Valuation60
Profitability75
Growth80
Balance Sheet Health70
Cash Flow85
Earnings Consistency88
FactorScore
Trend Analysis70
Momentum60
Volume Confirmation65
Support & Resistance60
MACD55

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (7)

Earnings Performance chevron_right

Consistent Earnings Beat

The company has consistently beaten earnings per share (EPS) estimates for the past four quarters, with surprises ranging from 1.31% to 7.53%.

Valuation chevron_right

Reasonable Price-to-Sales Ratio

The trailing Price-to-Sales (P/S) ratio of 2.2 is below the industry average and suggests that the company's sales are currently undervalued relative to its share price.

Show More 🔒
thumb_down

Bearish Points (7)

Valuation Risk chevron_right

Elevated Price-to-Earnings Ratio

The trailing P/E ratio of 42.2 is significantly higher than the company's historical averages and the broader market, suggesting potential overvaluation.

Growth Deceleration chevron_right

Slowing Revenue Growth

While revenue increased year-over-year, the rate of growth has decelerated from 18.1% in 2021 to 5.7% in 2024, indicating a potential slowdown in business expansion.

Show More 🔒

Calendar

July 2025

24

Next Earnings Date

EPS Est.
Revenue Est.

H: $4.27

A: $4.12

L: $4.04

H: 3.58B

A: 3.55B

L: 3.52B

August 2025

28

Ex-Dividend Date

September 2025

11

Next Dividend Date

Profile

Employees (FY)60.9K
ISINUS5049221055
FIGI-

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governments, physician, large provider organizations, other healthcare providers, hospitals and health systems, patients and consumers, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.

Seasonals

2025
2024
2023
2022
2021

Price Target

284.51 USD

The 39 analysts offering 1 year price forecasts for LH have a max estimate of 323.00 and a min estimate of 248.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
82.5M (99.46%)
Closely held shares
449K (0.54%)
82.9M
Free Float shares
82.5M (99.46%)
Closely held shares
449K (0.54%)

Capital Structure

Market cap
22.19B
Debt
7.27B
Minority interest
0.00
Cash & equivalents
1.52B
Enterprise value
27.95B

Valuation - Summary

Market Cap
22.2B
Net income
526M(2.37%)
Revenue
9.96B(44.87%)
22.2B
Market Cap
22.2B
Net income
526M(2.37%)
Revenue
9.96B(44.87%)
Price to earning ratio (P/E)42.20x
Price to sales ratio (P/S)2.20x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
13.01B
COGS
9.38B
Gross Profit
3.62B
OpEx
2.49B
Operating Income
1.14B
Other & Taxes
392M
Net Income
746M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒